Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide pharmacokinetics in children

S M Yule1, A V Boddy, M Cole

  • 1Department of Child Health, University of Newcastle upon Tyne, UK.

British Journal of Clinical Pharmacology
|January 1, 1996
PubMed
Summary

Cyclophosphamide pharmacokinetics in children with cancer show significant inter-patient variability. Factors like high doses and certain medications, including dexamethasone, allopurinol, and chlorpromazine, can alter cyclophosphamide

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.

British journal of clinical pharmacology·2018
Same author

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Pediatric blood & cancer·2017
Same author

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Pediatric blood & cancer·2016
Same author

RMP-7 : Potential as an Adjuvant to the Drug Treatment of Brain Tumours.

CNS drugs·2016
Same author

Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.

Journal of viral hepatitis·2014
Same author

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

British journal of cancer·2014

Area of Science:

  • Pharmacology
  • Pediatric Oncology
  • Drug Metabolism

Background:

  • Cyclophosphamide is a widely used chemotherapeutic agent in pediatric oncology.
  • Understanding its pharmacokinetic variability is crucial for optimizing treatment efficacy and minimizing toxicity in children.
  • Inter-patient differences in drug metabolism can significantly impact therapeutic outcomes.

Purpose of the Study:

  • To characterize the pharmacokinetic profile of cyclophosphamide in a cohort of children with cancer.
  • To investigate the influence of dose and concurrent medications on cyclophosphamide pharmacokinetics.
  • To identify factors contributing to inter-patient variability in cyclophosphamide disposition.

Main Methods:

  • Pharmacokinetic parameters of cyclophosphamide were measured in 38 pediatric cancer patients.

Related Experiment Videos

  • Analysis included half-life, clearance, and volume of distribution.
  • The impact of cyclophosphamide dose and co-administered drugs (dexamethasone, allopurinol, chlorpromazine) was assessed.

    • Main Results:

    • Significant inter-patient variability was observed in all measured pharmacokinetic parameters.
    • Cyclophosphamide half-life was prolonged at higher dose levels.
    • Prior dexamethasone treatment increased cyclophosphamide clearance, likely due to CYP450 induction.
    • Concomitant administration of allopurinol or chlorpromazine significantly increased cyclophosphamide half-life.

    Conclusions:

    • Cyclophosphamide pharmacokinetics in children exhibit substantial inter-patient variability.
    • Both the administered dose and concurrent drug therapies significantly influence cyclophosphamide metabolism.
    • These findings highlight the need for individualized dosing strategies to optimize cyclophosphamide's therapeutic effect in pediatric cancer patients.